Authored Content
The USPSTF develops independent, evidence-based preventive recommendations through an evidence-based review process. Avalere Health helps organizations successfully navigate, engage, and influence these processes.
Policymakers, professional societies, and advocates support the preservation of USPSTF’s evidence-based recommendations and independence amid reported plans for a sweeping overhaul.
Reported plans to reshape the USPSTF align with recent changes to ACIP and may shape the future of preventive care recommendations and access.
Avalere Health helps innovators shape USPSTF recommendations, driving preventive care access, payer coverage, and clinical adoption.
In Kennedy v. Braidwood, the Supreme Court affirmed HHS’s USPSTF appointment power, keeping the ACA’s no-cost preventive-service mandate fully in force.
If finalized, the President’s FY 2026 proposed budget cuts and restructuring of AHRQ is anticipated to impede key USPSTF activities.
The NIH recently announced plans to develop an RWE database to study autism spectrum disorders. In doing so, they can learn lessons encountered by life sciences companies developing data ecosystems for their products.
The Supreme Court weighs a case that could reshape access to no-cost preventive services under the ACA and redefine USPSTF's legal authority
Avalere assessed quality measurement, quality improvement, and value-based initiatives in rare disease and the opportunity for a cohesive quality strategy.
New USPSTF breast cancer screening recommendations may not address the disparities experienced by Black women.
When utilizing and acquiring data, life sciences companies should consider these top questions and key implications for their 2024–2025 strategic plans.
A major cyberattack has disrupted medical and pharmacy claims processing and is expected to impact how medical claims are submitted and paid in the future.
Continued emphasis on diabetes management technology and patient-centered care in updated clinical management standards highlight the importance of advancing quality measurement.
Innovative research methods can be used to measure the total burden of rare disease, including direct medical costs, indirect costs, and overall life impacts.